p-Tau217
p-Tau217 is tau protein phosphorylated at the 217th amino-acid residue.
p-Tau217 is tau protein phosphorylated at the 217th amino-acid residue. It is studied primarily as a blood-based biomarker of Alzheimer’s disease (AD)-related pathology rather than as a therapeutic drug target. Measurements are commonly performed in plasma, although p-tau217 may also be evaluated alongside cerebrospinal-fluid (CSF) biomarkers and imaging methods such as amyloid positron emission tomography (PET).
Across the provided literature, plasma p-tau217 is investigated in relation to amyloid beta (Aβ), particularly Aβ42, Aβ40, and the Aβ42/Aβ40 ratio; other biomarkers such as p-tau181, glial fibrillary acidic protein (GFAP), and neurofilament light chain (NF-L); and clinical outcomes including mild cognitive impairment, cognitive impairment, cognitive decline, and dementia. Its principal medical role is the assessment of amyloid pathology and the identification or monitoring of individuals within the Alzheimer’s disease continuum, including candidates for anti-amyloid therapy.
Where the papers sit
18 papers from the last 6 months study p-Tau217 directly · updated from PubMed 1 Nov 2026
Study type 0 clinical trials · 10 observational · 6 human data · 2 unclassified
Themes 3 themes
-
Plasma Amyloid Detection
Plasma p-tau217 is moving toward routine triage for amyloid pathology and eligibility for amyloid-targeting treatments. Lumipulse results are being tested against PET, Amyloid beta 42, p-tau181, and temporal-cortex pathology across platforms and clinical settings. Greater dynamic range supports detection of Alzheimer’s disease change, but discordance with amyloid status remains clinically important. Analytical robustness, multicenter validation, and performance in diverse memory-clinic populations remain central.
8 papers · 44.4%
-
Blood Biomarker Measurement
Blood-based p-tau217 measurement is moving toward accessible sampling, higher analytical sensitivity, and multiplex testing. Remote capillary samples show relationships with cognition, while short-interval variability makes collection timing and test-retest reliability important. Emerging platforms combine p-tau217 with Aβ42/Aβ40, GFAP, or other biomarkers in plasma and whole blood. The evidence remains focused on feasibility and measurement performance rather than established clinical endpoints.
5 papers · 27.8%
-
Cognitive Decline Prediction
Plasma p-tau217 is being used to forecast cognitive impairment and decline across obstructive sleep apnea, subjective cognitive decline, Down syndrome, and Alzheimer’s disease cohorts. Higher levels and faster longitudinal increases are linked to worse cognitive trajectories, with GFAP and neurodegeneration markers adding prognostic context. APOE ε4 appears to accelerate p-tau217 accumulation, supporting individualized risk models. Thresholds and model generalizability across populations remain unresolved.
5 papers · 27.8%
Papers
The 18 papers from the last 6 months that study p-Tau217 directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Plasma Amyloid Detection (8)
- Quantitative Relationship Between Lumipulse G Measures of pTau217 in Plasma and the Temporal Cortex. Neurology · 6 Oct 2026 PMID 42837647
- Long term clinical performance and analytical robustness of the Lumipulse plasma p-tau217 assay in routine clinical practice. Alzheimer's & dementia : the journal of the Alzheimer's Association · 28 Sept 2026 PMID 42805946
- Clinical utility of LUMIPULSE plasma p-tau217 to identify amyloid positivity among candidates for amyloid-targeting treatments in a real-world cohort. Alzheimer's & dementia (Amsterdam, Netherlands) · 25 Sept 2026 PMID 42787809
- Validation of plasma core biomarkers of Alzheimer's disease: A multicenter study in usual practice conditions. Journal of Alzheimer's disease : JAD · 16 Sept 2026 PMID 42746979
- Brain-derived plasma p-tau217 shows enhanced dynamic range for Alzheimer's disease neuropathological change. Alzheimer's & dementia : the journal of the Alzheimer's Association · 1 Sept 2026 PMID 42677463
- Head-to-head comparison of plasma biomarker assays across platforms for amyloid pathology in a multicenter cohort. Science bulletin · 23 Aug 2026 PMID 42633973
- Exploring longitudinal relationships among Alzheimer's disease biomarkers. Alzheimer's & dementia : the journal of the Alzheimer's Association · 31 Jul 2026 PMID 42535261
- Plasma phosphorylated tau217 discordance with amyloid status in an ethnically diverse mixed memory clinic cohort. Journal of the neurological sciences · 13 Jun 2026 PMID 42287769
Blood Biomarker Measurement (5)
- PMID 42091863
- Short-interval variability and test-retest reliability of Alzheimer's disease plasma biomarkers in a clinically heterogenous cohort. Alzheimer's research & therapy · 28 Oct 2026 PMID 42947225
- Subpicogram-Level Quantification of Trace Biomarkers Using an Automated High-Sensitivity Chemiluminescence Immunoassay Technology Based on a Novel Substrate Enhancement Strategy. Analytical chemistry · 20 Oct 2026 PMID 42899535
- Multiplexed EDL-FET biosensor with tannic acid stabilization for simultaneous p-Tau217 and Aβ42/Aβ40 detection in plasma and whole blood from stroke patients. Analytica chimica acta · 26 Aug 2026 PMID 42648826
- Differences in Neurofilament Light Chain, Glial Fibrillary Acidic Protein, and Tau Protein Levels in Patients with Temporal Lobe Epilepsy and Comorbid Depression. Molecular neurobiology · 26 May 2026 PMID 42189430
Cognitive Decline Prediction (5)
- APOE ε4 accelerates plasma p-tau217 trajectory: a Bayesian joint longitudinal analysis of ADNI. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 23 Oct 2026 PMID 42909513
- Plasma p-tau217 and neurodegeneration-related biomarkers predict incident cognitive impairment in obstructive sleep apnea: a prospective cohort study. Sleep & breathing = Schlaf & Atmung · 12 Oct 2026 PMID 42862512
- Dementia risk factors and biomarkers in subjective cognitive decline: real world evidence from the monza brain health service. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 29 Sept 2026 PMID 42809041
- The link between plasma and cognitive markers for Alzheimer's disease in Down syndrome: a longitudinal study. Journal of neurology · 24 Sept 2026 PMID 42786385
- Prognostic Value of Blood-Based P-Tau217 Levels for Progression to Cognitive Impairment. JAMA · 15 Jul 2026 PMID 42449500
By study type
Observational studies and case reports (10)
- Plasma P-Tau217 and NfL Longitudinal Changes Across Neurodegenerative Diseases: Impact of α-Synuclein in Alzheimer Disease. Neurology · 2 Nov 2026 PMID 42970748
- Short-interval variability and test-retest reliability of Alzheimer's disease plasma biomarkers in a clinically heterogenous cohort. Alzheimer's research & therapy · 28 Oct 2026 PMID 42947225
- APOE ε4 accelerates plasma p-tau217 trajectory: a Bayesian joint longitudinal analysis of ADNI. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 23 Oct 2026 PMID 42909513
- Plasma p-tau217 and neurodegeneration-related biomarkers predict incident cognitive impairment in obstructive sleep apnea: a prospective cohort study. Sleep & breathing = Schlaf & Atmung · 12 Oct 2026 PMID 42862512
- Quantitative Relationship Between Lumipulse G Measures of pTau217 in Plasma and the Temporal Cortex. Neurology · 6 Oct 2026 PMID 42837647
- The link between plasma and cognitive markers for Alzheimer's disease in Down syndrome: a longitudinal study. Journal of neurology · 24 Sept 2026 PMID 42786385
- Head-to-head comparison of plasma biomarker assays across platforms for amyloid pathology in a multicenter cohort. Science bulletin · 23 Aug 2026 PMID 42633973
- Exploring longitudinal relationships among Alzheimer's disease biomarkers. Alzheimer's & dementia : the journal of the Alzheimer's Association · 31 Jul 2026 PMID 42535261
- Prognostic Value of Blood-Based P-Tau217 Levels for Progression to Cognitive Impairment. JAMA · 15 Jul 2026 PMID 42449500
- Plasma phosphorylated tau217 discordance with amyloid status in an ethnically diverse mixed memory clinic cohort. Journal of the neurological sciences · 13 Jun 2026 PMID 42287769
Human data, design not indexed (6)
- Subpicogram-Level Quantification of Trace Biomarkers Using an Automated High-Sensitivity Chemiluminescence Immunoassay Technology Based on a Novel Substrate Enhancement Strategy. Analytical chemistry · 20 Oct 2026 PMID 42899535
- Dementia risk factors and biomarkers in subjective cognitive decline: real world evidence from the monza brain health service. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 29 Sept 2026 PMID 42809041
- Long term clinical performance and analytical robustness of the Lumipulse plasma p-tau217 assay in routine clinical practice. Alzheimer's & dementia : the journal of the Alzheimer's Association · 28 Sept 2026 PMID 42805946
- Brain-derived plasma p-tau217 shows enhanced dynamic range for Alzheimer's disease neuropathological change. Alzheimer's & dementia : the journal of the Alzheimer's Association · 1 Sept 2026 PMID 42677463
- Multiplexed EDL-FET biosensor with tannic acid stabilization for simultaneous p-Tau217 and Aβ42/Aβ40 detection in plasma and whole blood from stroke patients. Analytica chimica acta · 26 Aug 2026 PMID 42648826
- Differences in Neurofilament Light Chain, Glial Fibrillary Acidic Protein, and Tau Protein Levels in Patients with Temporal Lobe Epilepsy and Comorbid Depression. Molecular neurobiology · 26 May 2026 PMID 42189430
Unclassified: not yet indexed with MeSH (2)
- Clinical utility of LUMIPULSE plasma p-tau217 to identify amyloid positivity among candidates for amyloid-targeting treatments in a real-world cohort. Alzheimer's & dementia (Amsterdam, Netherlands) · 25 Sept 2026 PMID 42787809
- Validation of plasma core biomarkers of Alzheimer's disease: A multicenter study in usual practice conditions. Journal of Alzheimer's disease : JAD · 16 Sept 2026 PMID 42746979
Written from 18 PubMed abstracts, each one listed by PMID above. Published: 2026-09-26. Drafted by language models from published abstracts; not medical advice.